BeOne Medicines (ONC) Share-based Compensation (2015 - 2026)

BeOne Medicines (ONC) has 12 years of Share-based Compensation data on file, last reported at $123.4 million in Q1 2026.

• Quarterly Share-based Compensation rose 29.2% year-over-year to $123.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $538.7 million (up 20.14% YoY) and the FY2025 annual result came in at $510.9 million, up 15.68% from the prior year.
• Share-based Compensation steadied at $123.4 million in Q1 2026 per ONC's latest filing, from $123.8 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $150.8 million in Q2 2025 and bottomed at $65.6 million in Q1 2022.
• The 5-year median for Share-based Compensation is $96.0 million (2023), against an average of $102.7 million.
• The widest annual swing landed in 2022, when Share-based Compensation soared 43.03%; it then gained 7.68% in 2025.
• Tracing ONC's Share-based Compensation over 5 years: stood at $78.1 million in 2022, then grew by 18.94% to $92.9 million in 2023, then climbed by 15.82% to $107.6 million in 2024, then increased by 15.0% to $123.8 million in 2025, then decreased by 0.33% to $123.4 million in 2026.
• Per Business Quant, the three latest ONC Share-based Compensation figures stand at $123.4 million (Q1 2026), $123.8 million (Q4 2025), and $140.8 million (Q3 2025).

Peer Comparison